Funding for this research was provided by:
Daiichi-Sankyo (not available)
Text and Data Mining valid from 2020-01-08
Received: 7 November 2019
Accepted: 23 December 2019
First Online: 8 January 2020
Compliance with ethical standards
: Gregory Y.H. Lip, MD, has served as a consultant for Bayer/Janssen, Bristol-Myers Squibb/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi Sankyo, and as a speaker for Bayer, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi Sankyo. Monika Kozieł reported no conflict of interest. Naab Al-Saady, MD, is an employee of Covance, the CRO during the conduction of the study. Søren P. Hjortshøj, MD, has received honoraria for lectures and participation on advisory boards from Biotronik, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, and Pfizer. Assen Goudev, MD, has received honoraria for lectures and participation on advisory boards for AstraZeneca, Novartis, and Pfizer. Kurt Huber, MD, has received lecture fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer. Ariel Cohen, MD, reports a research grant from RESICARD; he has served as a consultant for Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, and Novartis. James Jin, PhD is employed by Daiichi Sankyo Pharma Development. Michael Melino and Shannon M. Winters, MS, were employed by Daiichi Sankyo at the time the study was conducted. Andreas Goette, MD, has served as a consultant for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer, and a speaker for AstraZeneca, Bayer, Berlin-Chemie, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Pfizer, and Sanofi-Aventis.